Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R R Osborn

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Pulmonary Pharmacology & Therapeutics|April 20, 1999
Effect of SB 217242 on hypoxia-induced cardiopulmonary changes in the high altitude-sensitive ratD C Underwood, S Bochnowicz, R R Osborn, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 1, 1993
Inhibition of antigen-induced bronchoconstriction and eosinophil infiltration in the guinea pig by the cyclic AMP-specific phosphodiesterase inhibitor, rolipramD C Underwood, R R Osborn, L B Novak, et al.
Biochemical and Biophysical Research Communications|December 28, 1983
2-nor-leukotriene analogs: antagonists of the airway and vascular smooth muscle effects of leukotriene C4, D4 and E4J G Gleason, T W Ku, M E McCarthy, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 24, 1998
Antiasthmatic activity of the second-generation phosphodiesterase 4 (PDE4) inhibitor SB 207499 (Ariflo) in the guinea pigD C Underwood, S Bochnowicz, R R Osborn, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 1, 1989
The bronchopulmonary pharmacology of SK&F 104353 in anesthetized guinea pigs: demonstration of potent and selective antagonism of responses to peptidoleukotrienesT J Torphy, J F Newton, M A Wasserman, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|October 29, 2000
SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lungD C Underwood, R R Osborn, S Bochnowicz, et al.
Advances in Prostaglandin, Thromboxane, and Leukotriene Research|January 1, 1987
Pharmacologic profile of SK&F 104353, a novel, highly potent and selective peptidoleukotriene antagonistM A Wasserman, T J Torphy, D W Hay, et al.
Pulmonary Pharmacology|January 1, 1991
Pharmacologic and pharmacokinetic profile of SK&F S-106203, a potent, orally active peptidoleukotriene receptor antagonist, in guinea-pigD W Hay, R M Muccitelli, L M Vickery-Clark, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 29, 2000
SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistenceD C Underwood, R R Osborn, C J Kotzer, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 9, 2001
Identification of a selective nonpeptide antagonist of the anaphylatoxin C3a receptor that demonstrates antiinflammatory activity in animal modelsR S Ames, D Lee, J J Foley, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Pulmonary Pharmacology & Therapeutics|April 20, 1999
Effect of SB 217242 on hypoxia-induced cardiopulmonary changes in the high altitude-sensitive ratD C Underwood, S Bochnowicz, R R Osborn, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 1, 1993
Inhibition of antigen-induced bronchoconstriction and eosinophil infiltration in the guinea pig by the cyclic AMP-specific phosphodiesterase inhibitor, rolipramD C Underwood, R R Osborn, L B Novak, et al.
Biochemical and Biophysical Research Communications|December 28, 1983
2-nor-leukotriene analogs: antagonists of the airway and vascular smooth muscle effects of leukotriene C4, D4 and E4J G Gleason, T W Ku, M E McCarthy, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 24, 1998
Antiasthmatic activity of the second-generation phosphodiesterase 4 (PDE4) inhibitor SB 207499 (Ariflo) in the guinea pigD C Underwood, S Bochnowicz, R R Osborn, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 1, 1989
The bronchopulmonary pharmacology of SK&F 104353 in anesthetized guinea pigs: demonstration of potent and selective antagonism of responses to peptidoleukotrienesT J Torphy, J F Newton, M A Wasserman, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|October 29, 2000
SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lungD C Underwood, R R Osborn, S Bochnowicz, et al.
Advances in Prostaglandin, Thromboxane, and Leukotriene Research|January 1, 1987
Pharmacologic profile of SK&F 104353, a novel, highly potent and selective peptidoleukotriene antagonistM A Wasserman, T J Torphy, D W Hay, et al.
Pulmonary Pharmacology|January 1, 1991
Pharmacologic and pharmacokinetic profile of SK&F S-106203, a potent, orally active peptidoleukotriene receptor antagonist, in guinea-pigD W Hay, R M Muccitelli, L M Vickery-Clark, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 29, 2000
SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistenceD C Underwood, R R Osborn, C J Kotzer, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 9, 2001
Identification of a selective nonpeptide antagonist of the anaphylatoxin C3a receptor that demonstrates antiinflammatory activity in animal modelsR S Ames, D Lee, J J Foley, et al.
Pageof 4